- Roche (RHHBY.OB) throws in the towel on its patent for the breast cancer drug Herceptin in India.
- The decision comes as the Indian government looks set to issue a compulsory license which would essentially nullify the patent and pave the way for cheaper versions of the expensive treatment.
- "It’s a completely face-saving thing,” Kalyani Menon-Sen, a campaigner for affordable medicines tells FT. "They know the patent is on wobbly grounds, and they know the compulsory license is coming through," she adds.
- Pharmaceutical sales in India totaled just 0.2% of the company's global pharmaceutical sales in 2012, WSJ notes.
Roche abandons Herceptin patent in India
Aug 17 2013, 19:38 ET